PACTR201605001602542招募中未知
A Demonstration Project of Antiretroviral-based HIV-1 Prevention Among High-risk HIV-1 Serodiscordant Couples in Nigeria
ational Agency for the Control of AIDS0 个研究点目标入组 600 人开始时间: 2016年4月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 55 Year(s)(—)
- 性别
- All
入选标准
- •For heterosexual couples:
- •1). Sexually active (defined as having had vaginal intercourse at least 6 times in the previous three months)
- •2). Willing to enter the study as a couple and intending to remain as a couple for the next 12 months
- •3). Has not been on PrEP medication prior to enrollment in study
- •For HIV-1 uninfected members of the couple (partner participants):
- •1). Able and willing to provide written informed consent
- •2). HIV-1 uninfected based on negative HIV-1 rapid tests, both at study screening and at the enrolment visit
- •3).Adequate renal function, defined by normal creatinine levels and estimated creatinine clearance ¿60 mL/min
- •4). Not currently pregnant or breastfeeding
- •5).Not currently enrolled in an HIV-1 prevention clinical trial
- •6). Not currently using PrEP
- •7). Enrolment of individuals with active and serious infections or active clinically significant medical problems will be at the discretion of the site investigator
- •For HIV-1 infected members of the couple (index participants):
- •1) Able and willing to provide written informed consent
- •2). HIV-1 infected based on positive rapid HIV-1 tests, according to national algorithm
- •3). No history of WHO stage III or IV conditions
- •4). Not currently using ART
- •5). Currently using ART but viral load still higher than 5,000 copies/ml
- •6). Not currently enrolled in an HIV-1 treatment study.
- •7). Current pregnancy or breastfeeding do not disqualify a candidate who is infected.
排除标准
- •1. Currently on ART and virally suppressed
研究者
相似试验
尚未招募
1 期
Immunological and Virucidal effect of Amrita Tablet for Prevention of HIV AIDSCTRI/2024/01/062079Satyananda yoga and Ayurveda Research institute Motihari
已完成
不适用
A clinical trial of R-CHOP with antiretroviral therapy for newly diagnosed CD20 positive AIDS-related non-Hodgkin lymphomaewly diagnosed CD20 positive AIDS-related non-Hodgkin lymphomaJPRN-UMIN000001452AIDS Clinical Center42
已完成
不适用
Development of the new HIV testing system and surveillance of HIV incidence in MSMHIV infectionJPRN-UMIN000018699AIDS Clinical Center, National Center for Global Health and Medicine1,000
进行中(未招募)
1 期
Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FASTHIV positive age > 18 years -newly diagnosed HIV-infected individual evidenced by any tests -antiretroviral-treatment naive -negative urine pregnancy test -willing to sign an informed written consent– -regular health insurance -willing to provide two distinct contact information (telephone number and/or email) in order to be easily reached if needed between Day 0 and Day 7EUCTR2019-000812-27-FRIMEA110
已完成
不适用
A randomised controlled trial of mobile phones to influence adherence to first line antiretroviral treatment among human immunodeficiency virus (HIV) infected patients in South IndiaHuman immunodeficiency virus (HIV)Infections and InfestationsISRCTN79261738European Union (EU) (Belgium)600
